Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $5.99, for a total value of $99,835.33. Following the completion of the sale, the insider directly owned 1,209,840 shares of the company’s stock, valued at approximately $7,246,941.60. The trade was a 1.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.25, for a total value of $104,168.75.
• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.45, for a total value of $124,169.15.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $6.04 on Monday. Xeris Biopharma Holdings, Inc. has a one year low of $3.81 and a one year high of $10.08. The business’s fifty day moving average is $6.33 and its 200 day moving average is $7.29. The stock has a market capitalization of $1.04 billion, a PE ratio of -603.40 and a beta of 0.77. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%. On average, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on XERS. Barclays assumed coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective on the stock. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in XERS. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the fourth quarter valued at approximately $25,000. AlphaQuest LLC bought a new position in Xeris Biopharma in the third quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after acquiring an additional 5,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.